全文获取类型
收费全文 | 33178篇 |
免费 | 2238篇 |
国内免费 | 783篇 |
专业分类
耳鼻咽喉 | 76篇 |
儿科学 | 1222篇 |
妇产科学 | 4538篇 |
基础医学 | 4001篇 |
口腔科学 | 160篇 |
临床医学 | 2301篇 |
内科学 | 3375篇 |
皮肤病学 | 255篇 |
神经病学 | 2301篇 |
特种医学 | 470篇 |
外国民族医学 | 18篇 |
外科学 | 2622篇 |
综合类 | 4981篇 |
现状与发展 | 5篇 |
预防医学 | 1702篇 |
眼科学 | 68篇 |
药学 | 2818篇 |
19篇 | |
中国医学 | 1201篇 |
肿瘤学 | 4066篇 |
出版年
2024年 | 40篇 |
2023年 | 336篇 |
2022年 | 571篇 |
2021年 | 1177篇 |
2020年 | 931篇 |
2019年 | 865篇 |
2018年 | 872篇 |
2017年 | 1108篇 |
2016年 | 1102篇 |
2015年 | 1065篇 |
2014年 | 1824篇 |
2013年 | 2186篇 |
2012年 | 1577篇 |
2011年 | 1830篇 |
2010年 | 1515篇 |
2009年 | 1422篇 |
2008年 | 1568篇 |
2007年 | 1541篇 |
2006年 | 1618篇 |
2005年 | 1406篇 |
2004年 | 1152篇 |
2003年 | 1110篇 |
2002年 | 945篇 |
2001年 | 846篇 |
2000年 | 779篇 |
1999年 | 600篇 |
1998年 | 477篇 |
1997年 | 499篇 |
1996年 | 509篇 |
1995年 | 431篇 |
1994年 | 410篇 |
1993年 | 357篇 |
1992年 | 360篇 |
1991年 | 331篇 |
1990年 | 339篇 |
1989年 | 272篇 |
1988年 | 205篇 |
1987年 | 184篇 |
1986年 | 196篇 |
1985年 | 255篇 |
1984年 | 241篇 |
1983年 | 155篇 |
1982年 | 191篇 |
1981年 | 151篇 |
1980年 | 131篇 |
1979年 | 118篇 |
1978年 | 102篇 |
1977年 | 81篇 |
1976年 | 63篇 |
1975年 | 46篇 |
排序方式: 共有10000条查询结果,搜索用时 218 毫秒
1.
Emeline Colomba Patricia Pautier Fanny Pommeret Alexandra Leary 《Expert review of anticancer therapy》2019,19(6):437-446
Introduction: The landscape of poly (ADP-ribose) polymerase (PARP) inhibition in ovarian cancer is rapidly evolving and becoming increasingly complex. Ovarian cancer is leading therapeutic innovation by providing the proof of concept for DNA repair as a target. Three different PARP inhibitors have now received approvals in the US and Europe in different indications. Subtle but crucial differences can be found among the licensed indications for each PARP inhibitor in terms of histology, type of BRCA mutation (germline and/or somatic), number of prior lines of chemotherapy and whether the indication is in the treatment or maintenance settings.
Areas covered: We review the latest clinical data regarding the PARP inhibitor rucaparib in ovarian cancer, provide an update on the evolving landscape of PARP inhibition in ovarian cancer, and summarize avenues of ongoing and future research.
Expert opinion: All eligible patients should be offered a PARP inhibitor. SOLO1 trial results demonstrated an unprecedented benefit maintenance with PARP inhibitors in first line. Results from trials evaluating PARP inhibitors as maintenance in first line regardless of BRCA status and from trials evaluating combinatorial strategies are eagerly awaited. 相似文献
2.
《Obstetrics, Gynaecology and Reproductive Medicine》2020,30(6):175-183
Menopause is generally experienced as a biopsychosocial process involving physiological changes, and influenced by a wide range of psychological, social and cultural factors. The loss of ovarian oestrogen production may cause debilitating symptoms, including hot flushes, night sweats, sleep disturbance, vaginal dryness, dyspareunia, bladder dysfunction, loss of libido, and mood changes. Experience of the menopause transition varies widely between individuals, depending on the age of onset, personal health and wellbeing, social context, environment and culture.Hormone Replacement Therapy (HRT) remains the most effective treatment for the management of vasomotor symptoms and vaginal dryness, but has no proven role in the treatment of chronic diseases of ageing. Treatment should be individualized, and for most healthy women aged 50–59 years the risks of HRT are low. An understanding of the pathophysiology of menopausal symptoms and the risks and benefits of both hormonal and non-hormonal treatments assists in the individual management of patients. 相似文献
3.
4.
绝经是一个古老的概念,见诸于文献,最早可以追溯到春秋时期中医的重要文献之一《黄帝内经》。其中,《素问·上古天真论》有这样的描述:“女子二七而天葵至,任脉通,太冲脉盛,月事以时下,故有子……七七任脉虚,太冲脉衰少,天葵竭,地道不通,故形坏而无子也。”绝经是卵巢功能衰竭所造成的一种生命现象,从理论上讲,经过长期的进化的洗礼,人体所有的器官和组织,都是维持人体生命活动不可或缺的重要组成部分。时至今日,在不同的流行病学调查中,女性平均绝经年龄仍保持在50岁左右[1-2],可谓亘古未变,而变化的是人类寿命的延长,2018年北京女性预期寿命已经达84.63岁。
浏览更多请关注本刊微信公众号及当期杂志。 相似文献
5.
目的:探讨甲状旁腺激素(PTH)对大鼠牵张成骨(DO)过程中ONC、OPN、C-FOS、COL1、VEGF、RUNX2、ALP基因表达的影响。方法30只雄性大鼠制备大鼠下颌骨DO模型。随机分5组,每组6只。第1组(只有牵张无PTH),术后8周取材,应用HE染色及微CT检测,以确定成骨情况。第2组(有牵张无PTH),第3组(有牵张有PTH),第4组(无牵张有PTH),第5组(对照组:无牵张无PTH)。2、3、4组及对照组术后1周取材,RT-PCR测定ONC、OPN、C-FOS、COL1、VEGF、RUNX2、ALP基因的表达。结果第1组,新骨形成,骨质充满牵张区,骨质连续,大鼠建模成功。RT-PCR检测结果显示,2、3、4组与对照组比较,OPN、COL1、RUNX2、ALP基因表达有明显提高(P<0.05),其中第3组最为明显。ONC、C-FOS、VEGF基因2、3、4组与对照组比较差异无统计学意义(P>0.05)。结论 PTH在 DO 过程中,间歇性给以 PTH的作用只有在牵张期发挥作用,其对 OPN、COL1、RUNX2、ALP基因表达能够获得理想的协同作用。 相似文献
6.
Elisa Malacarne Marta Devesa Francisca Martinez Ignacio Rodriguez Buenaventura Coroleu 《Journal of assisted reproduction and genetics》2020,37(12):3069
PurposeBreast cancer is the most common cancer diagnosed during childbearing age, and fertility preservation is becoming increasingly more essential. However, recent studies indicate a possible poorer response to controlled ovarian hyperstimulation (COH) in cancer patients than in non-cancer controls and a negative impact of BRCA mutations on female fertility. This study aims to evaluate ovarian response and the number of mature oocytes (MII) vitrified in women with breast cancer, with or without BRCA mutation, comparing them to the expected response according to an age-related nomogram.MethodsThis is a retrospective observational study involving sixty-one breast cancer patients who underwent COH for oocyte cryopreservation. The age-specific nomogram was built using 3871 patients who underwent COH due to oocyte donation, fertility preservation for non-medical reasons, or FIVET for male factor exclusively.ResultsThe mean number of oocytes retrieved was 13.03, whereas the mean number of MII oocytes was 10.00. After the application of the z-score, no statistically significant differences were found compared with the expected response in the general population, neither by dividing patients according to the presence or absence of BRCA mutation nor according to the phase in which they initiated stimulation.ConclusionThe results obtained do not support the notion of a negative impact of the BRCA mutation on the ovarian response of women with breast cancer. Women with breast cancer undergoing COH for fertility preservation can expect the ovarian response predicted for their age. 相似文献
7.
目的:探讨彩色多普勒超声诊断卵巢肿瘤蒂扭转的临床意义。方法方便选取2012―2015年该院收治的58例疑似卵巢肿瘤蒂扭转患者作为观察目标,入选病例均应用彩色多普勒超声进行检查,并将检查结果同术后病理检查结果进行比较。结果58例患者中,术后病理证实卵巢肿瘤蒂扭转者51例,彩色多普勒超声共确诊49例,检查准确率为96.1%;囊壁增厚、腹腔或盆腔积液、可见混合型团块是卵巢肿瘤蒂扭转的主要彩超表现。结论卵巢肿瘤蒂扭转应用彩色多普勒超声诊断,可显著提高诊断准确率,具有积极的临床使用和推广价值。 相似文献
8.
9.
10.
Dominique Trudel Luminita-Mihaela Avarvarei Michèle Orain Stéphane Turcotte Marie Plante Jean Grégoire Reinhild Kappelhoff David P. Labbé Dimcho Bachvarov Bernard Têtu Christopher M. Overall Isabelle Bairati 《Pathology, research and practice》2019,215(6):152369
Ovarian carcinoma is one of the most lethal malignancies, but only very few prognostic biomarkers are known. The degradome, comprising proteases, protease non-proteolytic homologues and inhibitors, have been involved in the prognosis of many cancer types, including ovarian carcinoma. The prognostic significance of the whole degradome family has not been specifically studied in high-grade serous ovarian cancer. A targeted DNA microarray known as the CLIP-CHIP microarray was used to identify potential prognostic factors in ten high-grade serous ovarian cancer women who had early recurrence (<1.6 years) or late/no recurrence after first line surgery and chemotherapy. In women with early recurrence, we identified seven upregulated genes (TMPRSS4, MASP1/3, SPC18, PSMB1, IGFBP2, CFI – encoding Complement Factor I – and MMP9) and one down-regulated gene (ADAM-10). Using immunohistochemistry, we evaluated the prognostic effect of these 8 candidate genes in an independent cohort of 112 high-grade serous ovarian cancer women. Outcomes were progression, defined according to CA-125 criteria, and death. Multivariate Cox proportional hazard regression models were done to estimate the associations between each protein and each outcome. High ADAM-10 expression (intensity of 2–3) was associated with a lower risk of progression (adjusted hazard ratio (HR): 0.51; 95% confidence interval (CI): 0.29-0.87). High complement factor I expression (intensity 2–3) was associated with a higher risk of progression (adjusted HR: 2.30, 95% CI: 1.17–4.53) and death (adjusted HR: 3.42; 95% CI: 1.72–6.79). Overall, we identified the prognostic value of two proteases, ADAM-10 and complement factor I, for high-grade serous ovarian cancer which could have clinical significance. 相似文献